Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D7QHV6
|
|||
| Drug Name |
ABBV-184
|
|||
| Drug Type |
TCR-T cell therapy
|
|||
| Indication | Acute myeloid leukaemia [ICD-11: 2A60; ICD-9: 205] | Phase 1 | [1] | |
| Non-small-cell lung cancer [ICD-11: 2C25.Y; ICD-9: 162] | Phase 1 | [1] | ||
| Company |
AbbVie
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | T-cell surface glycoprotein CD3 (CD3) | Target Info | . | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04272203) A Study to Determine Safety, Tolerability, Pharmacokinetics, and Recommended Phase 2 Dose (RP2D) of Intravenous ABBV-184 in Adult Participants With Previously Treated Cancers. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of AbbVie. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.